How ANKTIVA is Administered ----
https://anktiva.com/patients/how-anktiva-is-administered/
_____
For Approved NMIBC Treatment (No Apheresis): Anktiva is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in combination with BCG.
In this setting, it is administered via a catheter directly into the bladder (intravesical), and does not require apheresis or chemotherapy.
For Experimental CAR-NK/Memory Cell Therapy (Requires Apheresis):
When used in combination with Memory Cytokine-Enriched Natural Killer (M-ceNK) cells—such as in trials for glioblastoma or pancreatic cancer—the treatment involves apheresis to collect the patient’s own immune cells for activation and expansion outside the body, followed by re-infusion.
____
Crucial Administration Information:
Do Not Use Sub-Q:
The FDA-approved label explicitly states: "Do NOT administer by subcutaneous or intravenous or intramuscular routes".
Method:
It is delivered by a healthcare provider into the bladder via a catheter.
Indication:
It is used for BCG-unresponsive NMIBC.
U.S. Food and Drug Administration (.gov)
Note:
While search results indicate Anktiva is being studied in clinical trials for other solid tumors (such as non-small cell lung cancer) where subcutaneous administration is being investigated, the approved method for bladder cancer is solely intravesical.
https://anktiva.com/patients/how-anktiva-is-administered/
_____
For Approved NMIBC Treatment (No Apheresis): Anktiva is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in combination with BCG.
In this setting, it is administered via a catheter directly into the bladder (intravesical), and does not require apheresis or chemotherapy.
For Experimental CAR-NK/Memory Cell Therapy (Requires Apheresis):
When used in combination with Memory Cytokine-Enriched Natural Killer (M-ceNK) cells—such as in trials for glioblastoma or pancreatic cancer—the treatment involves apheresis to collect the patient’s own immune cells for activation and expansion outside the body, followed by re-infusion.
____
Crucial Administration Information:
Do Not Use Sub-Q:
The FDA-approved label explicitly states: "Do NOT administer by subcutaneous or intravenous or intramuscular routes".
Method:
It is delivered by a healthcare provider into the bladder via a catheter.
Indication:
It is used for BCG-unresponsive NMIBC.
U.S. Food and Drug Administration (.gov)
Note:
While search results indicate Anktiva is being studied in clinical trials for other solid tumors (such as non-small cell lung cancer) where subcutaneous administration is being investigated, the approved method for bladder cancer is solely intravesical.
9
